Predoctoral Research Associate - Summer 2027
Adimab
Summary
Adimab is the leading technology provider for therapeutic antibody drug discovery. Our Predoctoral Program is a 24-month opportunity that provides meaningful experience in an innovative, entrepreneurial environment. The program is designed for individuals looking to gain two years of industry experience before moving on to a PhD program.
Job description
As an Adimab predoc, you will work on innovative science and have the opportunity to make an immediate impact in cutting-edge antibody drug discovery and engineering. Using Adimab's state-of-the-art yeast-based antibody discovery platform, you will work with a team of experienced scientists on both partner-funded discovery projects as well as internal technology development initiatives.
Program Highlights
- Meaningful experience working on cutting-edge human antibody and TCR discovery and engineering campaigns in partnership with some of the most successful drug development companies and institutions in the world
- Experience designing and executing wet-lab and computational experiments while applying theories and applications from your undergraduate studies
- The ability to support research initiatives designed by senior scientists and the opportunity to develop your own technology development projects
- Exposure to a fast-paced environment, including insight into the strategic decision-making process of an innovative biotech
- Career development training, including application assistance, workshops on scientific writing, internal and external presentation skills, resume building, and networking
- Professional and skills development for becoming an independent and rigorous scientist
Responsibilities
- Design of protein engineering strategies for antibody and TCR discovery campaigns
- Implementation and process development of Adimab's yeast-based antibody and TCR discovery platforms
- Yeast antibody and TCR library construction, high-throughput antibody and TCR selections and analysis by flow cytometry
- Designing, characterizing, and structurally analyzing antibody- and TCR-derived therapeutic modalities
- Compiling, communicating, and presenting scientific findings to project teams
- Average 40–45-hour work week
- Assist with weekend lab coverage occasionally (varies by group)
Needed Upon Hire
- Bachelor's degree with experience in any of the following: protein engineering, biochemistry, molecular biology, immunology, chemical and biomedical engineering, or related disciplines. No prior yeast or antibody experience is required
- 2+ years of research experience
- Adaptable and productive in a fast-paced environment
- Ability to communicate effectively and openly with colleagues and supervisors
- Demonstrated scientific curiosity and drive
Requirements
- Bachelor's degree in protein engineering, biochemistry, molecular biology, immunology, chemical and biomedical engineering, or related disciplines
- 2+ years of research experience
- Adaptable and productive in a fast-paced environment
- Ability to communicate effectively and openly with colleagues and supervisors
- Demonstrated scientific curiosity and drive
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Paid Vacation
- Paid Sick Leave
- Company Shutdown Leave
- Graduate School Application Leave
- Catered Meals
- Health Club Membership
- Employee Referral Bonus
- 401(k) With Employer Match
- Equity
- Life Insurance
- Disability Insurance
- Relocation Assistance
- Graduate Application Fee Assistance
- Graduate School Visit Travel Assistance
Company overview
Adimab is a premier biotechnology company specializing in human antibody discovery and engineering, founded in 2007 and headquartered in Lebanon, New Hampshire. The company has established itself as one of the most successful antibody discovery companies in the industry, with over 600 discovery campaigns and more than 80 clinical programs created through partnerships with over 130 biopharmaceutical companies. Adimab's unique yeast-based platform provides a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. The company's technology combines in vitro speed with eukaryotic quality to deliver superior therapeutic candidates across various modalities including IgGs, multispecifics, CARs, and T cell engagers. With a team of approximately 139 employees, Adimab has built an extensive therapeutic pipeline and maintains collaborative relationships ranging from major pharmaceutical companies to emerging biotech firms and leading academic institutions. The company's approach emphasizes quality and developability from the start, preparing molecules for successful clinical development and commercialization.